What are some of the department's most satisfying successes of the past year and why? In the past year, we secured a jury trial win for Puma Biotechnology in the first federal securities class action to reach a verdict in nearly 10 years, and litigated multi-billion dollar disputes from both sides of the V—winning more than $1 billion for UBS Securities in a New York Supreme Court bench trial and staving off a $6 billion class certification decision for Facebook. Our collaborative nature also paid dividends for our clients. In a trifecta for our securities litigation & professional liability and Supreme Court & appellate practices, three separate SDNY victories were successfully affirmed in the Second Circuit—for Eaton, Endo, and Ferrellgas. We're also constantly looking ahead of the curve for our clients. For example, Latham has been at the forefront of the direct listing, an innovative alternative to the IPO. The first and only firm to advise on both the issuer and financial adviser side of a direct listing, Latham is uniquely positioned to help our clients understand the complex and novel Section 11 liability issues raised by this new method of going public.